Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
For patients on long-term methotrexate, less frequent lab monitoring may be just as safe. A large observational study found no meaningful difference in liver, blood count, or fibrosis outcomes between 3-month and 6-month monitoring intervals. Researchers say it may be time to revisit current guidelines — and lighten the load on both patients and the healthcare system.
For rheumatology patients on long-term methotrexate (MTX), how often do labs really need to be checked? A new study suggests the answer might be less often than current practice dictates. Researchers analyzed over 14,000 lab encounters from nearly 2,500 patients over nine years and found that those monitored every 6 months fared no worse than those checked every 3 months — with no meaningful differences in liver enzymes, blood counts, or fibrosis markers.
In fact, patients on the 6-month schedule were equally or less likely to develop abnormal lab results, with most comparisons showing no statistically significant difference. The only notable finding: 6-month monitoring was actually protective against elevated mean corpuscular volume (MCV > 100 fL).
Key Takeaways:
Why it matters: Current guidelines recommend frequent lab monitoring for MTX patients, but this study challenges whether that frequency adds clinical value — or just burden. Revisiting these intervals could meaningfully improve patient experience and reduce unnecessary healthcare utilization without compromising safety.
